Effects of Chronic PPAR-Agonist Treatment on Cardiac Structure and Function, Blood Pressure, and Kidney in Healthy Sprague-Dawley Rats

Figure 8

(a) Plasma adiponectin; (b) serum glucose; (c) Urinary aldosterone levels; (d) % Change in Plasma volume; and (e) Systolic blood pressure in normal male SD rats chronically treated with vehicle (VEH) or rosiglitazone at the dose of 80 mg/kg⋅body weight (RGZ), (𝑛=10/treatment group). Data were represented as means ± SEM. Means were compared using unpaired t-test. *indicates a significant difference between the groups (𝑝<0.05).

(a)

(b)

(c)

(d)

(e)